These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 37515190)
1. An Overview of the Conventional and Novel Methods Employed for SARS-CoV-2 Neutralizing Antibody Measurement. Rocha VPC; Quadros HC; Fernandes AMS; Gonçalves LP; Badaró RJDS; Soares MBP; Machado BAS Viruses; 2023 Jul; 15(7):. PubMed ID: 37515190 [TBL] [Abstract][Full Text] [Related]
2. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Yi C; Sun X; Ye J; Ding L; Liu M; Yang Z; Lu X; Zhang Y; Ma L; Gu W; Qu A; Xu J; Shi Z; Ling Z; Sun B Cell Mol Immunol; 2020 Jun; 17(6):621-630. PubMed ID: 32415260 [TBL] [Abstract][Full Text] [Related]
3. Optimized Pseudotyping Conditions for the SARS-COV-2 Spike Glycoprotein. Johnson MC; Lyddon TD; Suarez R; Salcedo B; LePique M; Graham M; Ricana C; Robinson C; Ritter DG J Virol; 2020 Oct; 94(21):. PubMed ID: 32788194 [TBL] [Abstract][Full Text] [Related]
4. Structural Basis of a Human Neutralizing Antibody Specific to the SARS-CoV-2 Spike Protein Receptor-Binding Domain. Yang M; Li J; Huang Z; Li H; Wang Y; Wang X; Kang S; Huang X; Wu C; Liu T; Jia Z; Liang J; Yuan X; He S; Chen X; Zhou Z; Chen Q; Liu S; Li J; Zheng H; Liu X; Li K; Yao X; Lang B; Liu L; Liao HX; Chen S Microbiol Spectr; 2021 Oct; 9(2):e0135221. PubMed ID: 34643438 [TBL] [Abstract][Full Text] [Related]
5. Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding. Byrnes JR; Zhou XX; Lui I; Elledge SK; Glasgow JE; Lim SA; Loudermilk RP; Chiu CY; Wang TT; Wilson MR; Leung KK; Wells JA mSphere; 2020 Sep; 5(5):. PubMed ID: 32938700 [TBL] [Abstract][Full Text] [Related]
6. [SARS-CoV-2 neutralizing monoclonal antibodies and nanobodies: a review]. Chen Y; Lin J; Zheng P; Cao M; Jin T Sheng Wu Gong Cheng Xue Bao; 2022 Sep; 38(9):3173-3193. PubMed ID: 36151792 [TBL] [Abstract][Full Text] [Related]
7. Nanoluciferase-based cell fusion assay for rapid and high-throughput assessment of SARS-CoV-2-neutralizing antibodies in patient samples. Meyrath M; Szpakowska M; Plesseria JM; Domingues O; Langlet J; Weber B; Krüger R; Ollert M; Chevigné A; Methods Enzymol; 2022; 675():351-381. PubMed ID: 36220277 [TBL] [Abstract][Full Text] [Related]
8. Analysis of a SARS-CoV-2-Infected Individual Reveals Development of Potent Neutralizing Antibodies with Limited Somatic Mutation. Seydoux E; Homad LJ; MacCamy AJ; Parks KR; Hurlburt NK; Jennewein MF; Akins NR; Stuart AB; Wan YH; Feng J; Whaley RE; Singh S; Boeckh M; Cohen KW; McElrath MJ; Englund JA; Chu HY; Pancera M; McGuire AT; Stamatatos L Immunity; 2020 Jul; 53(1):98-105.e5. PubMed ID: 32561270 [TBL] [Abstract][Full Text] [Related]
9. Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody. Pinto D; Park YJ; Beltramello M; Walls AC; Tortorici MA; Bianchi S; Jaconi S; Culap K; Zatta F; De Marco A; Peter A; Guarino B; Spreafico R; Cameroni E; Case JB; Chen RE; Havenar-Daughton C; Snell G; Telenti A; Virgin HW; Lanzavecchia A; Diamond MS; Fink K; Veesler D; Corti D Nature; 2020 Jul; 583(7815):290-295. PubMed ID: 32422645 [TBL] [Abstract][Full Text] [Related]
10. The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies. Zhang S; Gao C; Das T; Luo S; Tang H; Yao X; Cho CY; Lv J; Maravillas K; Jones V; Chen X; Huang R J Immunol Methods; 2022 Apr; 503():113244. PubMed ID: 35218866 [TBL] [Abstract][Full Text] [Related]
12. A SARS-CoV-2 neutralizing antibody selected from COVID-19 patients binds to the ACE2-RBD interface and is tolerant to most known RBD mutations. Bertoglio F; Fühner V; Ruschig M; Heine PA; Abassi L; Klünemann T; Rand U; Meier D; Langreder N; Steinke S; Ballmann R; Schneider KT; Roth KDR; Kuhn P; Riese P; Schäckermann D; Korn J; Koch A; Chaudhry MZ; Eschke K; Kim Y; Zock-Emmenthal S; Becker M; Scholz M; Moreira GMSG; Wenzel EV; Russo G; Garritsen HSP; Casu S; Gerstner A; Roth G; Adler J; Trimpert J; Hermann A; Schirrmann T; Dübel S; Frenzel A; Van den Heuvel J; Čičin-Šain L; Schubert M; Hust M Cell Rep; 2021 Jul; 36(4):109433. PubMed ID: 34273271 [TBL] [Abstract][Full Text] [Related]
13. Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex. Laurini E; Marson D; Aulic S; Fermeglia M; Pricl S ACS Nano; 2020 Sep; 14(9):11821-11830. PubMed ID: 32833435 [TBL] [Abstract][Full Text] [Related]
14. Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors. Weidenbacher PA; Waltari E; de Los Rios Kobara I; Bell BN; Morris MK; Cheng YC; Hanson C; Pak JE; Kim PS Nat Chem Biol; 2022 Nov; 18(11):1270-1276. PubMed ID: 36076082 [TBL] [Abstract][Full Text] [Related]
15. Correlation of SARS-CoV-2 Viral Neutralizing Antibody Titers with Anti-Spike Antibodies and ACE-2 Inhibition among Vaccinated Individuals. Grunau B; Prusinkiewicz M; Asamoah-Boaheng M; Golding L; Lavoie PM; Petric M; Levett PN; Haig S; Barakauskas V; Karim ME; Jassem AN; Drews SJ; Sediqi S; Goldfarb DM Microbiol Spectr; 2022 Oct; 10(5):e0131522. PubMed ID: 36121252 [TBL] [Abstract][Full Text] [Related]
16. Human neutralizing antibodies elicited by SARS-CoV-2 infection. Ju B; Zhang Q; Ge J; Wang R; Sun J; Ge X; Yu J; Shan S; Zhou B; Song S; Tang X; Yu J; Lan J; Yuan J; Wang H; Zhao J; Zhang S; Wang Y; Shi X; Liu L; Zhao J; Wang X; Zhang Z; Zhang L Nature; 2020 Aug; 584(7819):115-119. PubMed ID: 32454513 [TBL] [Abstract][Full Text] [Related]